Figure 5.

Improved functional and pathologic recovery in ischemic muscles after treatment with MSC^{E−selectin−GFP}. (A) Quantitative analysis of distance ran (m) prior to exhaustion in treatment groups (Vehicle = 4, MSC^GFP = 7, MSC^{E−selectin−GFP} = 10), **P < 0.01 via ANOVA). (B) Representative image of MSC^GFP vs. MSC^{E−selectin−GFP} on treadmill. (C) Qualitative analysis of the mean myofiber size of the ischemic calf muscle, data are based on 5 section/sample/mouse (μm², mean ± SD, **P < 0.01 via ANOVA, *P < 0.05 post-hoc Tukey Simultaneous Tests for Differences of Means, Vehicle treatment n = 3, MSC^GFP treatment n = 3, MSC^{E−selectin−GFP} treatment n = 3). (D) Representative images of transverse H&E sections of ischemic calf muscle in Vehicle, MSC^GFP, and MSC^{E−selectin−GFP}.